Laropiprant
Phase 1Small molecule
Merck & Co.Laropiprant is one of 29 small molecule programs targeting Erythema. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Erythema
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Lamprene
NovartisApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Botulinum Toxin a
GSKApproved
Trimethoprim-Sulfamethoxazole
AstellasApproved
Alphagan
NovartisPhase 3
Ceftin
GGlaxo Dba Glaxosmithkline
Approved
Rhofade
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Laropiprant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company